 "Kiran Mazumdar Shaw, Biocon CMD")
After acquiring Viatris’ biosimilars business for a whopping $3.3 billion, Biocon Biologics (BBL) is looking to launch an initial public offering in the next 18-24 months, said BBL executive chairperson Kiran Mazumdar-Shaw on Monday.
The cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder will be funded by debt, additional equity or a combination of the two, the firm said.
“The debt that BBL is taking on to finance this transaction will be financed by equity infusion by existing shareholders and the IPO. This deal will be value accretive
